Pronunciation: VEN-la-FAX-een HYE-droe-KLOR-ide
Class: Serotonin-norepinephrine reuptake inhibitor (SNRI)
- Capsules, ER 37.5 mg
- Capsules, ER 75 mg
- Capsules, ER 150 mg
- Tablets 25 mg
- Tablets 37.5 mg
- Tablets 50 mg
- Tablets 75 mg
- Tablets 100 mg
- Tablets, ER 37.5 mg
- Tablets, ER 75 mg
- Tablets, ER 150 mg
- Tablets, ER 225 mg
Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in the CNS by inhibiting their neuronal reuptake.
Absolute bioavailability is 45% and a single oral dose is well absorbed (at least 92%). Steady-state concentrations of venlafaxine and O-desmethylvenlafaxine (ODV) in plasma are attained within 3 days of oral dosing. Exhibits linear kinetics over dose range of 75 to 450 mg/day. For ER, C max is 150 ng/mL (260 ng/mL for ODV) and T max is 5.5 h (9 h for ODV).
Vd is 7.5 L/kg (5.7 L/kg for ODV); 27% of venlafaxine and 30% of ODV is protein bound.
Extensively metabolized in the liver. The major metabolite is ODV, which is active.
Renal elimination of venlafaxine and its metabolite is the primary route of excretion. Within 48 h, 87% is recovered in urine. Elimination half-life is 5 h (11 h for ODV).
Special PopulationsRenal Function Impairment
Dosage adjustment is necessary with CrCl 10 to 70 mL/min. Venlafaxine elimination half-life was prolonged approximately 50% and Cl was reduced approximately 24%; ODV elimination half-life was prolonged 40% although Cl was unchanged.Dialysis
Dose adjustment is necessary. Venlafaxine elimination half-life was prolonged approximately 180% and Cl was reduced approximately 57%. ODV elimination half-life was prolonged approximately 142% and Cl was reduced 56%.Hepatic Function Impairment
In patients with hepatic cirrhosis, dosage adjustment is necessary. Venlafaxine elimination half-life was prolonged by approximately 30% and Cl decreased 50%; ODV elimination half-life was prolonged approximately 60% and Cl decreased 30%.Elderly
Pharmacokinetics not altered by age.Gender
Pharmacokinetics not altered by gender.Poor/Extensive metabolizers
Venlafaxine plasma concentrations were higher in CYP2D6 poor metabolizers than in extensive metabolizers. AUC of venlafaxine and ODV were similar in poor and extensive metabolizers. No dosage adjustment is required.
Indications and UsageER capsules, ER tablets, immediate-release tablets
Major depressive disorder (MDD).ER capsules, ER tablets
Social anxiety disorder.ER capsules
Generalized anxiety disorder; panic disorder.
Autism; binge eating disorder; hot flashes; pain; premenstrual dysphoric disorder; posttraumatic stress disorder; prevention of migraine.
Concomitant use with MAOIs; hypersensitivity to venlafaxine or any component in the formulation.
Dosage and AdministrationGeneralized Anxiety Disorder
Adults (ER capsules)
PO 75 mg/day as single dose in the morning or evening, at approximately the same time once daily. Some patients may need to start at 37.5 mg/day for 4 to 7 days before increasing to 75 mg/day. Titrate to clinical effect in increments of up to 75 mg/day at intervals of no less than 4 days (max, 225 mg/day).Major Depressive Disorder
PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of at least 4 days (max, 375 mg/day).Adults (ER capsules, ER tablets)
PO 75 mg/day as single dose in the morning or evening, at approximately the same time once daily. Some patients may need to start at 37.5 mg/day for 4 to 7 days before increasing to 75 mg/day. Titrate to clinical effect in increments of up to 75 mg/day at intervals of no less than 4 days (max, 225 mg/day).Panic Disorder
Adults (ER capsules)
PO Start with 37.5 mg/day for 7 days as a single dose in the morning or evening, at approximately the same time once daily. After 7 days, the dosage may be increased to 75 mg/day for 7 days. Subsequent dosage increases should be in increments of up to 75 mg/day, as needed, and should be made at intervals of no less than 7 days (max, 225 mg/day).Social Anxiety Disorder
Adults (ER tablets, ER capsules)
PO 75 mg daily. There is no evidence that higher doses confer any additional benefit.Switching From Venlafaxine to Venlafaxine ER
Depressed patients on venlafaxine can be switched to venlafaxine ER at the nearest equivalent total daily dose.Switching Patients To and From MAOIs
When switching from an MAOI to venlafaxine, allow at least 14 days after discontinuing the MAOI before starting venlafaxine. Allow at least 7 days after discontinuing venlafaxine before starting an MAOI.Hepatic Function Impairment
PO Reduce total daily dose by 50% in patients with mild to moderate hepatic impairment. In patients with cirrhosis, it may be necessary to reduce the dose by more than 50%.Renal Function Impairment
PO Reduce ER total daily dose by 25% to 50% in patients with renal impairment (CrCl 10 to 70 mL/min). Reduce total daily dose of immediate-release by 25% in patients with mild to moderate renal impairment. Reduce total daily dose of ER and immediate-release by 50% in patients undergoing hemodialysis. Withhold dose until dialysis treatment is completed.
- Administer with food.
- It is generally agreed that acute episodes of MDD require several months or longer of sustained pharmacological therapy beyond response to the acute episode.
- Swallow venlafaxine ER capsules or tablets whole. Do not divide, crush, chew, or place in water.
- For patients who have difficulty swallowing venlafaxine ER capsules whole, the capsules may be opened and the contents sprinkled on a spoonful of applesauce. The drug/applesauce mixture should be swallowed immediately without chewing and followed with a glass of water. Do not prepare the mixture ahead of time and store.
Storage/StabilityER capsules and immediate-release tablets
Store between 68° and 77°F. Protect from moisture.ER tablets
Store between 59° and 86°F. Protect from moisture and humidity.
Drug InteractionsAspirin, NSAIDs
The risk of GI bleeding may be increased. Caution patients about the increased risk of bleeding.Azole antifungal agents (eg, ketoconazole)
Venlafaxine plasma levels may be elevated, increasing the risk of adverse reactions. Closely monitor the clinical response when starting or stopping an azole antifungal agent. Adjust the venlafaxine dose as needed.Bupropion
Unexpected adverse reactions, including serotonin syndrome, may occur. Closely monitor the patient. If an interaction is suspected, stop one or both drugs. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.Buspirone
Paradoxical worsening of obsessive-compulsive disorder or serotonin syndrome has been reported. If coadministration cannot be avoided, closely monitor the patient for worsening clinical status, as well as serotonin syndrome. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.Cimetidine
Venlafaxine plasma concentrations may be increased. Caution is advised in patients with hypertension or hepatic function impairment.Clozapine
Plasma levels of clozapine may be increased, increasing the pharmacologic effects and risk of adverse reactions. Monitor the clinical response and adjust the clozapine dose as needed when venlafaxine is started or stopped.CYP3A4 inhibitors
Venlafaxine plasma concentrations may be elevated, increasing the pharmacologic effects and risk of adverse reactions; use with caution.Cyproheptadine
Decreased pharmacologic effects of venlafaxine may occur. If coadministration cannot be avoided, closely monitor the clinical response. If an interaction is suspected, consider discontinuing cyproheptadine.Desipramine, haloperidol
Plasma levels of these drugs may be elevated by venlafaxine, increasing the risk of adverse reactions. Monitor plasma concentrations of these agents and the clinical response. Adjust the dose of these agents as needed.Dextromethorphan
Dextromethorphan plasma concentrations and risk of toxicity may be increased. If coadministration cannot be avoided, closely monitor the clinical response and adjust the dextromethorphan dose as needed.Fenfluramine, L-tryptophan
Serotonin syndrome may occur because of additive serotonergic effects. Concurrent use is not recommended.Indinavir
Plasma concentrations may be decreased by venlafaxine. The clinical importance of this is unknown. Use with caution and monitor the clinical response.Linezolid, lithium, metoclopramide, selective 5-HT 1 receptor agonists (eg, sumatriptan), sibutramine, SNRIs, SSRIs, St. John's wort, tramadol, trazodone
Serotonin syndrome, including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness, may occur. If coadministration cannot be avoided, closely monitor the patient for adverse reactions including signs and symptoms of serotonin syndrome. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.MAOIs (eg, phenelzine)
MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait at least 7 days after stopping venlafaxine before using MAOIs.Methylene blue
The risk of CNS toxicity, including serotonin syndrome, may be increased. Use an alternative agent for methylene blue.Methylphenidate, nefazodone, opioid analgesics (eg, meperidine), rasagiline
Serotonin syndrome may occur because of additive effects. Closely monitor the patient for adverse reactions. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.Metoprolol
Venlafaxine reduced the blood pressure–lowering effect of metoprolol. The clinical relevance of this finding is unknown; however, exercise caution with coadministration. Closely monitor blood pressure.Propafenone
Propafenone and venlafaxine plasma concentrations may be increased. Closely monitor for increased pharmacologic and toxic effects of propafenone and venlafaxine. Adjust treatment as needed.Sour date nut
The risk of serotonin syndrome may be increased. Advise patients taking venlafaxine to avoid sour date nut.Sympathomimetics (eg, amphetamine)
Increased sensitivity to sympathomimetics and increased risk of serotonin syndrome. Closely monitor the patient for adverse reactions, including signs and symptoms of serotonin syndrome. Serotonin syndrome requires immediate medical attention, including withdrawal of the serotonergic agent and supportive care.Terbinafine
Venlafaxine plasma concentrations may be elevated, increasing the pharmacologic and adverse reactions. Monitor the clinical response and observe the patient for adverse reactions. Adjust the venlafaxine dose as needed.Warfarin
Coadministration may increase PT, aPTT, or INR. Monitor coagulation parameters when starting or stopping venlafaxine and adjust the warfarin dose as needed. Caution patients about the increased risk of bleeding.
Laboratory Test Interactions
Venlafaxine may reduce uptake and diagnostic efficacy of iobenguane. False-negative iobenguane imaging tests may result.
Vasodilation (6%); hypertension (5%); palpitation (3%); tachycardia (2%); postural hypotension (1%); deep vein thrombophlebitis, ECG abnormalities (eg, QT prolongation), cardiac arrhythmias (including atrial fibrillation and torsades de pointes) (postmarketing).
Headache (38%); somnolence (26%); dizziness, insomnia (24%); nervousness (21%); asthenia (19%); anxiety (11%); tremor (10%); abnormal dreams (7%); agitation (5%); depression, hypertonia, paresthesia, twitching (3%); abnormal thinking, confusion (2%); depersonalization (1%); amnesia, hypesthesia, migraine, trismus, vertigo (at least 1%); catatonia, delirium, extrapyramidal symptoms, impaired coordination and balance, involuntary movements, panic, serotonin syndrome, shock-like electrical sensations (postmarketing).
Sweating (19%); rash (3%); pruritus (1%); erythema multiforme, Stevens-Johnson syndrome, TEN (postmarketing).
Abnormality of accommodation (9%); pharyngitis (7%); blurred vision (6%); abnormal vision (5%); mydriasis, taste perversion, tinnitus (2%); angle-closure glaucoma, eye hemorrhage (postmarketing).
Nausea (58%); dry mouth (22%); anorexia (17%); constipation (15%); abdominal pain, diarrhea, vomiting (8%); dyspepsia (7%); flatulence (4%); eructation, increased appetite (at least 1%); GI bleeding, pancreatitis (postmarketing).
Abnormal ejaculation (19%); decreased libido (8%); impotence (6%); orgasm disturbance (5%); anorgasmia (female), urinary frequency (3%); urination impaired (2%); albuminuria, metrorrhagia, prostatic disorder, vaginitis (at least 1%); urinary retention (1%).
Ecchymosis (at least 1%); agranulocytosis, aplastic anemia, neutropenia, pancytopenia (postmarketing).
Hepatic reactions, including elevated GGT, unspecified LFT abnormalities, liver damage, necrosis, or failure, and fatty liver (postmarketing).
Increased serum cholesterol (5%); increased CPK and LDH (postmarketing).
Weight loss (7%); edema, weight gain (at least 1%).
Bronchitis, cough increased, dyspnea (at least 1%); interstitial lung disease (postmarketing).
Yawn (8%); chills (7%); infection (6%); chest pain, trauma (2%); fever, neck pain, substernal chest pain (at least 1%); anaphylaxis, angioedema, congenital anomalies, hemorrhage, increased prolactin, night sweats, renal failure, rhabdomyolysis, SIADH (postmarketing).
Increased risk of suicidal thinking and behavior has been observed in children, adolescents, and young adults taking antidepressants for MDD and other psychiatric disorders. Appropriately monitor patients of all ages who are started on antidepressant therapy and observe them closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with their prescriber.
Monitor patients for clinical worsening, suicidality, and unusual changes in behavior, especially during the first few months of therapy or at times of dose changes, either increases or decreases, and during discontinuation of therapy. Monitor serum cholesterol levels in patients receiving long-term therapy. Monitor BP and heart rate at regular intervals.
Periodically reassess patient to determine need for maintenance treatment and the appropriate dose for such treatment.
Monitor patients with raised IOP or who are at risk of acute narrow-angle glaucoma.
Category C . Neonates exposed to venlafaxine late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.
Excreted in breast milk.
Safety and efficacy not established. Not approved for use in children. Growth rate reduction and weight loss may occur.
Take extra care when increasing dose in elderly patients.
Reduction of dose may be necessary. Use drug with caution.
Reduction of dose may be necessary. Use drug with caution.
May impair judgment, thinking, or motor skills.
Risk of bleeding events, ranging from ecchymosis to life-threatening hemorrhages, may be increased.
Activation of mania/hypomania
Has been reported. Use cautiously in patients with history of mania.
Treatment-emergent anorexia in adults and decreased appetite in children are more common in venlafaxine-treated patients compared with placebo.
Dose-related increases in supine systolic and diastolic BP may occur.
Use with caution in patients with diseases or conditions that could affect hemodynamic responses or metabolism and whose underlying medical conditions might be compromised by increases in heart rate (eg, heart failure, hyperthyroidism, recent MI).
Treatment-emergent anxiety, insomnia, and nervousness may occur.
Discontinuation of treatment
If treatment is to be discontinued or the dose reduced after more than 1 wk of therapy, gradually taper the dose and monitor patient for withdrawal symptoms. If significant withdrawal symptoms develop, reinstitute previous dosing schedule and attempt a less-rapid tapering regimen after patient has stabilized.
Mydriasis has been reported. Monitor patients with raised IOP or at risk of acute narrow-angle glaucoma.
Growth rate is decreased in children receiving venlafaxine compared with placebo. The differences in observed and expected growth rates were greater in children younger than 12 y of age compared with children 12 y of age and older.
Hyponatremia and/or SIADH may occur. Use with caution in elderly, volume-depleted, or diuretic-taking patients.
Interstitial lung disease and eosinophilic pneumonia
Because these conditions have been associated with venlafaxine, consider the possibility of these adverse reactions occurring in patients with progressive dyspnea, cough, or chest discomfort.
Screening for bipolar disorder
Screen patients with depression for risk of bipolar disorder prior to initiating therapy with an antidepressant.
Use with caution in patients with a history of seizures or with conditions that potentially lower the seizure threshold. Discontinue use if seizures occur.
Serotonin syndrome and NMS-like reactions
Potentially life-threatening serotonin syndrome, including mental status changes, or NMS-like reactions may occur.
Serum cholesterol levels increased in patients treated for at least 3 mo.
May cause sustained increases in BP.
A loss of 5% or more of body weight was reported in 7% of patients.
Bradycardia, bundle branch block, coma, death, hypotension, liver necrosis, mydriasis, paresthesia, prolonged QTc interval, rhabdomyolysis, seizures, serotonin syndrome, sinus tachycardia, somnolence, ventricular tachycardia, vertigo, vomiting.
- If patient is a child or adolescent being treated for depression, advise patient, family, or caregiver to read the Medication Guide About Using Antidepressants in Children and Teenagers before starting therapy and with each refill. Review face-to-face monitoring schedule required for use of drug in this situation.
- Advise patient that dose will be started low and then increased until max benefit is obtained.
- Instruct patient to take prescribed dose with food.
- Advise patient using venlafaxine ER capsules or tablets to swallow capsules whole. Caution patient not to separate, crush, or chew the capsules or tablets.
- Advise patient who has difficulty swallowing venlafaxine ER capsules whole that the capsules may be opened and the contents sprinkled on a spoonful of applesauce. The drug/applesauce mixture should be swallowed immediately without chewing and followed with a glass of water. Caution patient not to prepare the mixture ahead of time and store.
- Instruct patient not to stop taking the medication when they feel better.
- Caution patient that unless advised by health care provider not to take aspirin or aspirin-containing products, NSAIDs, Ginkgo biloba , or any other medication or herbal product that can affect coagulation because of increased risk of serious bleeding.
- Instruct patient to contact health care provider if symptoms do not appear to be getting better, are getting worse, or if bothersome adverse reactions (eg, changes in sexual function, diarrhea, excessive drowsiness, nausea, nervousness, tremors) occur.
- Advise patient to take frequent sips of water, suck on ice chips or sugarless hard candy, or chew sugarless gum if dry mouth occurs.
- Advise patient, family, or caregiver to notify health care provider if rash, hives, or other symptoms of an allergic reaction develop.
- Advise patient, family, or caregiver of patient being treated for depression to be alert for abnormal changes in mood or thinking and to immediately report any of the following to health care provider: agitation, akathisia (psychomotor restlessness), anxiety, change in mood, change in personality, hostility or aggressiveness, impulsivity, insomnia, irritability, panic attacks, suicidal thoughts or behavior. Advise families and caregivers of patients to observe for emergence on a day-to-day basis, because changes may be abrupt.
- Caution patient about the risk of serotonin syndrome with the concomitant use of venlafaxine and triptans, tramadol, tryptophan, or other serotonergic agents.
- Advise patient that if medication needs to be discontinued, it will be slowly withdrawn unless safety concerns (eg, rash) require a more rapid withdrawal.
- Instruct patient to avoid alcoholic beverages and sedatives or depressants (eg, diazepam) while taking medication.
- Advise patient with high BP to monitor BP at regular intervals.
- Advise patient that drug may impair judgment, thinking, or motor skills, or cause drowsiness, and to use caution while driving or performing other tasks requiring mental alertness or coordination until tolerance is determined.
Copyright © 2009 Wolters Kluwer Health.
More Venlafaxine Hydrochloride resources
- Venlafaxine Hydrochloride Monograph (AHFS DI)
- Venlafaxine Prescribing Information (FDA)
- Effexor Prescribing Information (FDA)
- Effexor Advanced Consumer (Micromedex) - Includes Dosage Information
- Effexor Consumer Overview
- Effexor MedFacts Consumer Leaflet (Wolters Kluwer)
- Effexor XR extended-release capsules MedFacts Consumer Leaflet (Wolters Kluwer)
- Effexor XR Prescribing Information (FDA)